STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALHC
  4. [Form 4] Alignment Healthcare, Inc. Insider Trading Activity

CEO of Alignment Healthcare (NASDAQ: ALHC) sells 298K shares via trust

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Alignment Healthcare, Inc. director and Chief Executive Officer John E. Kao reported indirect open-market sales of company common stock made through the JEK Trust, of which he is trustee. On June 10, 2026, the trust sold 223,064 shares at a weighted-average price of $20.5962 per share and 74,936 shares at a weighted-average price of $19.6481 per share, under a Rule 10b5-1 trading plan adopted on November 21, 2025. Following these transactions, the JEK Trust held 1,609,830 shares indirectly, while Mr. Kao’s direct holdings were 1,608,743 shares, after a transfer of 176,125 shares from direct ownership to the trust.

Positive

  • None.

Negative

  • None.
Insider KAO JOHN E
Role Chief Executive Officer
Sold 298,000 shs ($6.07M)
Type Security Shares Price Value
Sale Common Stock 74,936 $19.6481 $1.47M
Sale Common Stock 223,064 $20.5962 $4.59M
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 1,609,830 shares (Indirect, See Footnote); Common Stock — 1,608,743 shares (Direct, null)
Footnotes (1)
  1. Date of Rule 10b5-1 plan adoption: 11/21/2025 The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $19.12 to $20.11. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range. Balances in column 5 reflect the transfer of 176,125 shares held directly by Mr. Kao to the JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.12 to $20.89. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
First sale volume 223,064 shares Open-market sale on June 10, 2026
First sale price $20.5962 per share Weighted-average price for 223,064-share sale
Second sale volume 74,936 shares Open-market sale on June 10, 2026
Second sale price $19.6481 per share Weighted-average price for 74,936-share sale
Total shares sold 298,000 shares Aggregate open-market sales reported in Form 4
Indirect holdings after 1,609,830 shares JEK Trust holdings after June 10, 2026 sales
Direct holdings after 1,608,743 shares Direct holdings by John E. Kao after transfer to trust
10b5-1 plan adoption date November 21, 2025 Date Rule 10b5-1 trading plan was adopted
Rule 10b5-1 plan regulatory
"Date of Rule 10b5-1 plan adoption: 11/21/2025"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted-average price financial
"The reported price in column 4 is a weighted-average price."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
indirect financial
"direct_or_indirect": "I","nature_of_ownership": "See Footnote""
trustee financial
"of which Mr. Kao is the trustee."
A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KAO JOHN E
(Last)(First)(Middle)
1100 W. TOWN & COUNTRY RD., SUITE 1600
(Street)
ORANGE CALIFORNIA 92868
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/10/2026S(1)74,936D$19.6481(2)1,609,830(3)ISee Footnote(4)
Common Stock06/10/2026S(1)223,064D$20.5962(5)1,386,766(3)ISee Footnote(4)
Common Stock1,608,743(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Date of Rule 10b5-1 plan adoption: 11/21/2025
2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $19.12 to $20.11. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
3. Balances in column 5 reflect the transfer of 176,125 shares held directly by Mr. Kao to the JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.
4. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.
5. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.12 to $20.89. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
Remarks:
/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Alignment Healthcare (ALHC) disclose for John E. Kao?

Alignment Healthcare disclosed that CEO John E. Kao, through the JEK Trust he oversees, reported open-market sales of company common stock on June 10, 2026. The filing details two separate weighted-average price transactions and updated direct and indirect share holdings afterward.

How many Alignment Healthcare (ALHC) shares were sold in this Form 4 filing?

The Form 4 reports total open-market sales of 298,000 shares of Alignment Healthcare common stock. These consist of 223,064 shares in one transaction and 74,936 shares in a second transaction, both attributed to the JEK Trust associated with CEO John E. Kao.

At what prices were Alignment Healthcare (ALHC) shares sold in the reported transactions?

The filing shows weighted-average sale prices of $20.5962 per share for 223,064 shares and $19.6481 per share for 74,936 shares. Footnotes explain these averages reflect multiple trades within narrower intraday price ranges for Alignment Healthcare common stock.

Were the Alignment Healthcare (ALHC) insider sales made under a Rule 10b5-1 plan?

Yes. A footnote states the trading activity was conducted under a Rule 10b5-1 plan adopted on November 21, 2025. Such pre-arranged plans allow insiders to schedule trades in advance according to set instructions, independent of later nonpublic information.

What are John E. Kao’s direct and indirect Alignment Healthcare (ALHC) holdings after the trades?

After the reported transactions, John E. Kao directly held 1,608,743 shares of Alignment Healthcare common stock. Indirectly, through the JEK Trust where he serves as trustee, he was reported to hold an additional 1,609,830 shares according to the Form 4 disclosure.

What role does the JEK Trust play in the Alignment Healthcare (ALHC) Form 4?

The JEK Trust is identified as the indirect holder of the sold shares, with John E. Kao acting as trustee. Footnotes clarify that the trust holds Alignment Healthcare securities and that balances reflect a transfer of 176,125 shares from Mr. Kao’s direct ownership into this trust.